Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dexamethasone and Lower Extremity Block Duration

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by University of Chicago
Sponsor:
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT01756586
First received: December 20, 2012
Last updated: March 27, 2014
Last verified: March 2014
  Purpose

Dexamethasone has shown to prolong upper extremity blocks. No one ha studied its effect on lower extremity blocks. The study would evaluate that point.


Condition Intervention Phase
Analgesia Duration
Drug: Dexamethasone
Drug: Bupivacaine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • increase in the duration of block [ Time Frame: one year ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: February 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Control
Plain bupivacaine
Drug: Bupivacaine
Control
Experimental: Experimental
Bupivacaine with Dexamethasone
Drug: Dexamethasone Drug: Bupivacaine
Control

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-75
  2. foot surgery
  3. no contraindication to regional anesthesia

Exclusion Criteria:

  1. opioid dependent
  2. chronic pain condition
  3. peripheral neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01756586

Contacts
Contact: Tariq Malik, MD 773-834-3139 tmalik@dacc.uchicago.edu
Contact: Tariq Malik 773-834 3646 tmalik@dacc.uchicago.edu

Locations
United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Tariq Malik    773-834-3643    tmalik@dacc.uchicago.edu   
Contact: Tariq Malik       tmalik@dacc.uchicago.edu   
Principal Investigator: Tariq Malik, MD         
Sponsors and Collaborators
University of Chicago
  More Information

No publications provided

Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT01756586     History of Changes
Other Study ID Numbers: IRB12-2198
Study First Received: December 20, 2012
Last Updated: March 27, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Chicago:
popliteal block
analgesia duration

Additional relevant MeSH terms:
BB 1101
Bupivacaine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Anesthetics
Anesthetics, Local
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014